AHR antagonist 5 is a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397 (example 39; IC50< 0.5 μΜ). It significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1.

Tumor growth inhibition is statistically significant with AHR antagonist 5 as single. AHR antagonist 5 (10 mg/kg; p.o.; every day for 3 weeks) combination with anti-PD-1 significantly inhibited tumor growth inhibition compared to the anti-PD-1 alone.

2247953-39-3

C25H27Cl3FN7

550.89

AHR antagonist 5

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years